Compare ELVR & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELVR | SDGR |
|---|---|---|
| Founded | 2000 | 1990 |
| Country | Australia | United States |
| Employees | 230 | N/A |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.8M | 925.8M |
| IPO Year | N/A | 2020 |
| Metric | ELVR | SDGR |
|---|---|---|
| Price | $91.69 | $15.14 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $21.00 |
| AVG Volume (30 Days) | 70.1K | ★ 1.2M |
| Earning Date | 04-23-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.14 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $255,869,000.00 |
| Revenue This Year | $90.73 | $0.76 |
| Revenue Next Year | $42.59 | $4.60 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 23.29 |
| 52 Week Low | $15.55 | $10.95 |
| 52 Week High | $101.50 | $27.63 |
| Indicator | ELVR | SDGR |
|---|---|---|
| Relative Strength Index (RSI) | 57.12 | 73.89 |
| Support Level | $77.29 | $11.27 |
| Resistance Level | $101.50 | $19.51 |
| Average True Range (ATR) | 3.53 | 0.71 |
| MACD | -0.79 | 0.22 |
| Stochastic Oscillator | 61.09 | 91.87 |
Elevra Lithium Ltd is a mineral exploration and development company. The principal activity of the company is the identification, acquisition, and evaluation of mineral exploration assets, focusing on lithium. The projects of the company include the Moblan Lithium Project, the Carolina Lithium Project, the Ewoyaa Lithium Project, North American Lithium, and other projects. The company also holds an interest in a tenement portfolio in the Pilbara region, prospective for gold and lithium.
Schrodinger Inc is a healthcare-based software company. It offers software solutions designed to support and accelerate the discovery, design, and optimization of molecules. The company operates in two reportable segments: Software and Drug Discovery. The software segment is focused on selling software to transform drug discovery across the life sciences industry, as well as to customers in materials science industries. The drug discovery segment is focused on generating revenue from a diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have various stages of discovery and development. The majority of the company's revenue is derived from the Software segment. Geographically, it derives the maximum revenue from the United States.